Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (166)	8/27/2002 10:19:35 AM
From: Vector1	Read Replies (1) \| Respond to of 447

Thanks Miljenko. I generally agree with your conclusion: <<Speculative translation suggest that OSIP two PIII front line program have small chance to be better than Iressa data. Third PIII trial, monotherapy for progressive lung cancer, may generate positive data (like Iressa), but overall dug utility will be far from expected.>> However, I bought OSIP because: I believe the PIII trial for refactory lung cancer for Tarceva is well designed and if successful will give Tarceva a very high chance of approval. In addition I think that Tarceva has a strong chance of positive results in combo with Gemzar in Pancreatic Cancer. Gemzar is limited and will generate $800m in sales. I do not think IRESSA will get approval based on existing data leaving Tarceva potentially as the first approved product. OSIP has $500m in cash/ V1

To: Miljenko Zuanic who wrote (166)	12/25/2002 12:21:07 AM
From: fred hayes	Read Replies (1) \| Respond to of 447

>>Why both compound skipped PII combination trials???<< Good question, and sorry for the untimely response. Cleaning out some files tonight, too wound up from Christmas eve to go to bed yet. Looking at an OSIP press release dated may 17, 1999 re CP-358,774, which becomes Tarceva. First para last sentence, "A large scale Phase II clinical program testing the efficacy of CP-358,774 against a variety of tumors, both as a single agent and in combination with existing chemotherapy regimens, has been initiated." Really? Note that it says it has been initiated, not that they are thinking about it. But I have no notes or record of P2 results in combo therapy, and have been under the impression that no P2 combo trials with Tarceva have been done. Anybody have any recollection of P2 results with combo therapy? If not, what should we make of this statement from OSIP? Pretty clear that results from P2 combo trials would be pretty important in evaluating Tarceva's chances in light of what happened to Iressa. I don't know how to reconcile this info. Maybe I'm misreading it. Any thoughts? fred